NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its quarterly earnings data on Thursday, February, 13th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.10. The business had revenue of $18.10 million for the quarter, compared to analyst estimates of $16.48 million. Karyopharm Therapeutics had a negative return on equity of 227.13% and a negative net margin of 488.08%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 analysts have issued 1 year price targets for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $37.00. On average, they expect Karyopharm Therapeutics' share price to reach $22.33 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

News headlines about KPTI stock have trended somewhat negative on Thursday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Karyopharm Therapeutics.

Karyopharm Therapeutics saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 12,930,000 shares, an increase of 34.4% from the January 30th total of 9,620,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is currently 11.1 days. Approximately 24.2% of the shares of the company are sold short. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), Agios Pharmaceuticals (AGIO), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), Blueprint Medicines (BPMC), Allakos (ALLK), Ultragenyx Pharmaceutical (RARE), Genmab A/S (GMAB), Alkermes (ALKS), Emergent Biosolutions (EBS) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Micron Technology (MU), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Caladrius Biosciences (CLBS) and Clovis Oncology (CLVS).

Karyopharm Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (7.32%), State Street Corp (5.14%), Delphi Management Partners VIII L.L.C. (3.60%), Candriam Luxembourg S.C.A. (1.35%), Geode Capital Management LLC (1.32%) and FMR LLC (1.01%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, J. Goldman & Co LP, Palo Alto Investors LP, Candriam Luxembourg S.C.A., Schonfeld Strategic Advisors LLC, UBS Group AG and FMR LLC. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was bought by a variety of institutional investors in the last quarter, including Delphi Management Partners VIII L.L.C., Parkman Healthcare Partners LLC, Fairmount Funds Management LLC, Marshall Wace LLP, EAM Investors LLC, Renaissance Technologies LLC, California Public Employees Retirement System and EAM Global Investors LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $15.38.

Karyopharm Therapeutics has a market capitalization of $965.71 million and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]